JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D

Summary

This is a double-blind, randomized, placebo-parallel-controlled, multicenter study. The objective is to evaluate the efficacy and safety of Ivarmacitinib 8 mg administered for 52 weeks in preserving pancreatic β cell function in subjects with newly-onset type 1 diabetes mellitus. The study consists of a screening period (V1, up to 2 weeks), a 52-week double-blind treatment period (V2 to V14), and a 4-week safety follow-up period (V15).

Timeline

Start

2026-09-30

Primary completion

2029-08-31

Completion

2029-12-31

Drugs

Indications